Business Context and Reporting Period
Company: ImmunityBio, Inc. (IBRX)
Filing Type: Form 8-K (Current Report)
Date of Report: April 6, 2026
Reporting Period: Event-based report regarding regulatory correspondence dated April 6, 2026.
Key Financial Metrics
This filing is a regulatory disclosure and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
No material financial changes are reported in this document. The primary event is the submission of a comprehensive response to a Warning Letter issued by the U.S. Food and Drug Administration (FDA) Office of Prescription Drug Promotion on March 13, 2026.
Outlook, Risks, and Management Commentary
- Regulatory Action: The Company announced it has submitted a response to the FDA Warning Letter regarding prescription drug promotion.
- Corrective Actions: The press release (Exhibit 99.1) outlines immediate and planned corrective actions related to the FDA findings.
- Legal Status: The information in Item 7.01 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review the attached Press Release (Exhibit 99.1) for specific details on the FDA Warning Letter and the Company's corrective action plan.
- Verify the status of the FDA's review of the Company's response to determine potential impacts on marketing activities.
- Monitor future filings for any updates on regulatory compliance or additional enforcement actions.